Henogen opens new biopharmaceutical clinical supply plant

21-Oct-2004

The new biopharmaceutical clinical supply plant of Henogen was inaugurated today in a ceremony attended by the Wallonia Minister-President Jean-Claude Van Cauwenberghe. "These new cGMP facilities, dedicated to the mammalian cells culture, represent a total investment of 10 million Euros", said Dr Alex Bollen, CEO ; "they feature a park of 3L & 15L bioreactors used for process development purposes and a cGMP 300L bioreactor train, operated in both fed-batch and perfusion modes, able to deliver clinical-grade biologicals at a scale appropriate to the phase I to III clinical trials", he added.

This investment extends the existing know-how of Henogen 'from gene to clinical product' to the large scale production of clinical grade monoclonal antibodies and recombinant proteins made by mammalian cells, which is a very fast growing market.

These new facilities will generate additional revenues to the existing ones (forecast 2004: 7 MEUR) in order to boost the clinical development of its proprietary products e.g. a recombinant human tissue factor derivative, currently in clinical trials as well as other undisclosed programs.

Other news from the department manufacturing

These products might interest you

Biostat STR

Biostat STR by Sartorius

Biostat STR Generation 3 Bioreactors

Engineered for Ultimate Upstream Performance

bioreactors
Ambr® 250 HT Consumables

Ambr® 250 HT Consumables by Sartorius

Efficient bioprocesses with single-use bioreactors

Minimise cleaning effort and maximise flexibility for cell and microbial cultures

bioreactors
Ambr® 250 Modular

Ambr® 250 Modular by Sartorius

Mini bioreactors for cell and gene therapies with high scalability

Maximise your process development with reliable single-use vessels

bioreactors
Flexcell Systems

Flexcell Systems by Dunn

Flexcell Cell Stretching Bioreactors for Life Science Research

Used in over 1300 laboratories worldwide, and cited in over 4000 research publications

bioreactors
Brooks Instrument SLA Biotech-Serie

Brooks Instrument SLA Biotech-Serie by Brooks Instrument

Control bioprocesses efficiently and precisely with flow controllers for biotechnology applications

The SLA Biotech series has been developed specifically for the requirements in bioprocesses

mass flow controllers
SLAMf Biotech-Serie Massendurchflussregler

SLAMf Biotech-Serie Massendurchflussregler by Brooks Instrument

SLAMf Mass Flow Controllers Designed Specifically for Biotech (IP66 / NEMA 4X)

Special equipment for biotech process plants, suitable for splash water and high-pressure cleaning

mass flow controllers
Loading...

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous